

### **Amendment to the Claims**

The following listing of claims will replace all prior versions and listings of claims.

#### **Listing of Claims:**

1-23. (Canceled)

24. (Currently Amended) A method of diagnosing pancreatic cancer comprising:

(a) contacting a pancreatic biological sample from a test subject with an antibody or fragment thereof that specifically binds a protein whose amino acid sequence consists of amino acid residues 1 to 201 of SEQ ID NO:344;

(b) assaying the level of said protein in the pancreatic biological sample; and

(c) comparing the level of said protein in the pancreatic biological sample with the a standard-level of said protein in a non-cancerous pancreatic biological sample;

whereby an increase in the level of said protein in the pancreatic biological sample compared to the ~~standard~~-level of said protein in a non-cancerous pancreatic biological sample is indicative of pancreatic cancer.

25. (Currently Amended) The method of claim 24 wherein the biological sample is pancreatic tissue.

26. (Currently Amended) The method of claim 24 wherein the biological sample is pancreatic cells.

27-28. (Canceled)

29. (Previously Presented) The method of claim 24 wherein the antibody or fragment thereof is selected from the group consisting of:

- (a) a polyclonal antibody or fragment thereof;
- (b) a chimeric antibody or fragment thereof;
- (c) a humanized antibody or fragment thereof;
- (d) a single chain antibody; and

(e) a Fab fragment.

30. (Previously Presented) The method of claim 24 wherein the antibody or fragment thereof is human.

31. (Previously Presented) The method of claim 24 wherein the antibody or fragment thereof is monoclonal.

32. (Previously Presented) The method of claim 24 wherein the antibody or fragment thereof is labeled.

33. (Previously Presented) The method of claim 32 wherein the label is selected from the group consisting of:

- (a) an enzyme label;
- (b) a radioisotope;
- (c) a fluorescent label; and
- (d) biotin.

34. (Previously Presented) The method of claim 33 wherein the label is a radioisotope selected from the group consisting of:

- (a)  $^{125}\text{I}$ ;
- (b)  $^{121}\text{I}$ ;
- (c)  $^{131}\text{I}$ ;
- (d)  $^{112}\text{In}$ ; and
- (e)  $^{99\text{m}}\text{Tc}$ .

35. (Currently Amended) A method of diagnosing pancreatic cancer comprising:

(a) contacting a pancreatic biological sample from a test subject with an antibody or fragment thereof that specifically binds a protein whose amino acid sequence consists of the amino acid sequence of the full-length polypeptide encoded by the HRDFB85 cDNA contained in ATCC™ Deposit Number 209082;

(b) assaying the level of said protein in the pancreatic biological sample; and

(c) comparing the level of said protein in the pancreatic biological sample with the a standard-level of said protein in a non-cancerous pancreatic biological sample;

whereby an increase in the level of said protein in the pancreatic biological sample compared to the ~~standard-level~~ of said protein in a non-cancerous pancreatic biological sample is indicative of pancreatic cancer.

36. (Currently Amended) The method of claim 35 wherein the biological sample is pancreatic tissue.

37. (Currently Amended) The method of claim 35 wherein the biological sample is pancreatic cells.

38-39. (Canceled)

40. (Previously Presented) The method of claim 35 wherein the antibody or fragment thereof is selected from the group consisting of:

- (a) a polyclonal antibody or fragment thereof;
- (b) a chimeric antibody or fragment thereof;
- (c) a humanized antibody or fragment thereof;
- (d) a single chain antibody; and
- (e) a Fab fragment.

41. (Previously Presented) The method of claim 35 wherein the antibody or fragment thereof is human.

42. (Previously Presented) The method of claim 35 wherein the antibody or fragment thereof is monoclonal.

43. (Previously Presented) The method of claim 35 wherein the antibody or fragment thereof is labeled.

44. (Previously Presented) The method of claim 43 wherein the label is selected from the group consisting of:

- (a) an enzyme label;
- (b) a radioisotope;
- (c) a fluorescent label; and
- (d) biotin.

45. (Previously Presented) The method of claim 44 wherein the label is a radioisotope selected from the group consisting of:

- (a)  $^{125}\text{I}$ ;
- (b)  $^{121}\text{I}$ ;
- (c)  $^{131}\text{I}$ ;
- (d)  $^{112}\text{In}$ ; and
- (e)  $^{99\text{m}}\text{Tc}$ .